Ase Technology Says Unit Acquires Machinery Equipment From Marketech Int'L For T$1.46 Billion

Commercial Momentum Accelerates with Partnerships to Drive AI-Powered Scent Intelligence for IndustrialAI and HealthcareAI

SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 16, 2025 / Ainos, Inc. ("Ainos" or the "Company"), a pioneer in AI-powered scent digitization, today announced it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The compliance confirmation comes as Ainos gains momentum across its AI Nose platform, with strategic deployments, commercial partnerships, and a 90-day execution plan aimed at enabling large-scale commercialization by 2026.

"Over the past six months, we optimized our capital structure and delivered key milestones for the AI Nose platform, powered by our proprietary smell language model (SLM). We are positioning for a phase of accelerated deployment and scalable revenue generation across industrial, robotics, and healthcare sectors," said Eddy Tsai, Chairman and CEO of Ainos.

Recent AI Nose Milestones Driving Growth

• Strategic partnership with ASE Technology Holding (ASEH), the world's largest semiconductor packaging and testing company, with a targeted phased deployment plan of up to 15,000 AI Nose units.

• Expanded industrial footprint through partnerships with Kenmec and Solomon, aiming to integrate AI-powered scent intelligence powered by AI Nose and smell language model (SLM) into smart factory and machine vision ecosystems across Asia.

• Completed the world's first integration of AI Nose with a humanoid robot, for embedding digital olfactory sensing capabilities into ugo Inc.'s service robotics platform.

• Smell language model (SLM) surpassed 90% accuracy in classifying everyday scents, including meat, food, and beverages.

• Senior care program improved accuracy to ~85% from ~80%.

• 412% year-over-year revenue increase in Q1 2025, driven by initial AI Nose sales for the senior care program.

Key Strategic Priorities for the Next 90 Days

Building toward its 2026 scale-up, Ainos will focus on the following near-term priorities:

• Complete pilot deployment of approximately 1,400 AI Nose units with ASEH and initiate Phase 1 expansion to approximately 5,000 units.

• With Kenmec, exhibit the AI Nose integrated ugo robot at Automation Taipei, to be held August 20-23 in Taiwan.

• Drive SmellTech-as-a-Service (SaaS) as a subscription-based revenue model for AI Nose deployments and Smell ID services.

• Enhance SLM performance through broad-scale validation and expanded real-world testing.

• Pursue additional strategic partnerships in Asia and Europe for technology licensing and regional commercialization.

"Regaining Nasdaq compliance is just the beginning," Tsai added. "Our mission is to build a scalable, multi-revenue platform powered by scent intelligence, transforming smell into computable, actionable business data across global markets. I believe smell will be AI's next token."

On July 15, 2025, the Company received formal notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") confirming that Ainos' common stock maintained a closing bid price of $1.00 or higher for ten consecutive business days, from June 30, 2025 to July 14, 2025. According to the Notice, the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and this matter is now officially closed.

About Ainos, Inc.

Ainos, Inc. is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contact Information

Feifei Shen

ir@ainos.com

SOURCE: Ainos, Inc.

View the original press release on ACCESS Newswire

ASE Technology's unit, Siliconware Precision Industries, signed facility engineering contracts worth NT$689.9 million with Chung Yuang Electrical Consulting, according to a Monday Taiwan Exchange filing.

Shares gained 1% in the recent trading session on Tuesday.

The deals, which run from July 3, 2025, to Sept. 30, 2026, will support Siliconware Precision Industries' production and operational needs, the company said.

Technology stocks were advancing pre-bell Thursday as the Technology Select Sector SPDR Fund was up 0.2% and the SPDR S&P Semiconductor ETF was 0.3% higher recently.

Oracle will establish its first cloud services center in Indonesia in partnership with DayOne Data Centers Singapore, Bloomberg reported, citing people familiar with the matter. Shares of Oracle were up nearly 2% premarket.

Methode Electronics shares were down more than 19% after the company reported a wider fiscal Q4 adjusted net loss as net sales declined during the period.

ASE Technology shares were 0.5% higher after the company said its June net revenue was 49.51 billion New Taiwan dollars ($1.66 billion), up 5.5% from a year earlier.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust was up 0.02% and the actively traded Invesco QQQ Trust was 0.1% higher in Thursday's premarket activity amid Trump's latest tariffs and uncertainty around economic reports.

US stock futures were mixed, with S&P 500 Index futures up 0.04%, Dow Jones Industrial Average futures slipping 0.01%, and Nasdaq futures gaining 0.1% before the start of regular trading.

The weekly jobless claims bulletin will be released at 8:30 am ET, followed by the EIA natural gas report at 10:30 am ET.

Federal Reserve St. Louis President Alberto Musalem, Governor Christopher Waller, and San Francisco President Mary Daly speak on Thursday.

In premarket activity, bitcoin was up by 1.1% and the cryptocurrency fund ProShares Bitcoin Strategy ETF was 1.6% higher.

Power Play:

Consumer

The Consumer Staples Select Sector SPDR Fund was down 0.02%, while the Vanguard Consumer Staples Fund was flat. The iShares US Consumer Staples ETF was inactive, and the Consumer Discretionary Select Sector SPDR Fund gained 0.2%. The VanEck Retail ETF was inactive, while the SPDR S&P Retail ETF advanced by 0.02%.

WK Kellogg shares were up more than 53% pre-bell after Bloomberg News reported the company is close to being acquired by Ferrero International for approximately $3 billion.

Winners and Losers:

Health Care

The Health Care Select Sector SPDR Fund retreated 0.04%. The Vanguard Health Care Index Fund gained 0.1% while the iShares US Healthcare ETF was inactive. The iShares Biotechnology ETF was up 0.1%.

Nurix Therapeutics stock was up more than 19% premarket after the company reported a narrower-than-expected fiscal Q2 net loss and higher revenue.

Industrial

Industrial Select Sector SPDR Fund slipped by 0.03% while the Vanguard Industrials Index Fund was flat and the iShares US Industrials ETF (IYJ) was inactive.

Delta Air Lines stock was up more than 13% before the opening bell after the company reported higher-than-expected Q2 adjusted earnings and restored its full-year guidance.

Technology

Technology Select Sector SPDR Fund advanced 0.2%, and the iShares US Technology ETF was 0.2% higher, while the iShares Expanded Tech Sector ETF was inactive. Among semiconductor ETFs, SPDR S&P Semiconductor ETF was 0.2% higher, while the iShares Semiconductor ETF rose by 0.6%.

ASE Technology shares were up 3% in recent premarket activity after the company said its June net revenue was 49.51 billion New Taiwan dollars ($1.66 billion), up 5.5% from a year earlier.

Energy

The iShares US Energy ETF was down 0.7%, while the Energy Select Sector SPDR Fund declined by 0.2%.

Genesis Energy stock was down more than 1% before Thursday's opening bell after the company maintained its quarterly dividend at $0.165 per unit.

Financial

Financial Select Sector SPDR Fund retreated 0.1%. Direxion Daily Financial Bull 3X Shares was down 0.4%, while its bearish counterpart Direxion Daily Financial Bear 3X Shares was 0.2% higher.

Commodities

Front-month US West Texas Intermediate crude oil advanced 1.2% to $67.54 per barrel on the New York Mercantile Exchange. Natural gas retreated 0.1% to $3.21 per 1 million British Thermal Units. United States Oil Fund was 0.7% lower, while the United States Natural Gas Fund gained 0.8%.

Gold futures for August gained 0.3% to reach $3,332.10 an ounce on the Comex, while silver futures were up 0.9% at $36.69 an ounce. SPDR Gold Shares advanced 0.1%, and the iShares Silver Trust was 0.8% higher.

Ainos Pioneers SmellTech as the Next Sensory Frontier in Industrial AI

2H 2025 Industrial Pilots and Subscription Model Poised to Unlock Multi-Million Dollar Revenue Potential in 2026

SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 10, 2025 / Ainos, Inc. ("Ainos" or the "Company"), a pioneer in AI-powered scent detection, today announced that Water Tower Research ("WTR") has published a new report spotlighting Ainos' rapid commercial acceleration in industrial AI through its AI Nose. The report highlights a wave of high-impact partnerships, positioning AI Nose as an emerging digital olfaction platform across mission-critical industrial environments. These new alliances add significant growth potential in the Company's market expansion from healthcare to industrials, as AI Nose, powered by smell language model (SLM), transitions from R&D to scaled deployment in smart manufacturing, robotics, and semiconductor sectors.

Key Highlights from the Report:

• AI-powered SmellTech emerges as a critical layer of industrial intelligence: With the new partnerships, Ainos unlocks significant growth by expanding its digital olfaction platform beyond healthcare into industrial markets. By integrating AI Nose into manufacturing and automation environments, the Company is ready to fill a critical sensory gap in industrial AI, enabling real-time scent detection and advancing SmellTech commercialization across multiple industrial sectors such as semiconductors, robotics, and smart infrastructure.

• Expanded partnership with a semiconductor leader signals key inflection point in market penetration: Ainos and ASE Technology Holding, the world's largest provider of semiconductor assembly and testing services, plan to deploy up to 15,000 AI Nose units across ASE's key production sites through a multi-phase rollout, with 30+ use cases identified across predictive maintenance, environmental safety, and process optimization. WTR sees scope for the relationship to expand further given ASE's extensive global footprint across multiple countries and smart manufacturing implementation with 56 lights-out factories.

• Kenmec alliance accelerates integration across smart infrastructure: Kenmec is an automation and smart logistics solution provider. Kenmec will manufacture and deploy AI Nose across a wide range of infrastructure applications, including HVAC, logistics, airports, food monitoring, and medical facilities. This partnership establishes manufacturing scalability for Ainos and unlocks diverse deployment channels through Kenmec's broad client base in semiconductors, optoelectronics, green energy, healthcare, cold chain, and public infrastructure.

• Solomon alliance positions AI Nose at the core of Asia's next-gen industrial ecosystem: With a five-year agreement with Solomon Technology, a leader in machine vision, industrial AI, and smart automation, Ainos can fast-track AI Nose platform's adoption into Asia's key manufacturing sectors including semiconductors, petrochemicals and autonomous mobile robots (AMRs).Solomon's visual language model (VLM) complements Ainos' smell language model (SLM), enabling advanced sensor fusion and opening new possibilities in intelligent sensing.

• 2H 2025 roadmap lays foundation for a breakout 2026 with multi-million dollar recurring revenue potential: Ainos will commence scaled pilot programs for AI Nose across key industrial sectors in Asia during 2H 2025. These pilot deployments will serve as the onramp for Ainos' SmellTech-as-a-Service subscription model, potentially generating multi-million-dollar recurring revenues annually starting 2026.

Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=UR_AIMD_07092025

About Ainos, Inc.

Ainos, Inc. is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

Contact Information

Feifei Shen

ir@ainos.com

SOURCE: Ainos, Inc.

View the original press release on ACCESS Newswire

ASE Technology said Thursday its June net revenue was 49.51 billion New Taiwan dollars ($1.66 billion), up 5.5% from a year earlier.

The company's Q2 revenue increased 7.5% year over year to NT$150.75 billion.